Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology by Vincent, Jean-Louis
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
s
u
p
p
l
e
m
e
n
t
ATIII = antithrombin III; DIC = disseminated intravascular coagulation; PAI = plasminogen activator inhibitor; TF = tissue factor; TNF = tumour
necrosis factor.
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Introduction
Sepsis, the host response to infection, involves a series of
clinical, hematological, inflammatory and metabolic
responses that can ultimately lead to organ failure. Severe
sepsis is typically associated with activation of the coagu-
lation system, leading to deposition of thrombin in the
microvasculature. This process is associated first with
activation, and then with inhibition of fibrinolysis. It is also
associated with an inflammatory response and changes in
microvascular permeability. These alterations, which are
recognized by the clinician as disseminated intravascular
coagulation (DIC), are commonly associated with multiple
organ dysfunction, and have important prognostic implica-
tions. DIC, therefore, can be seen as both a thrombotic
and a bleeding disorder, as an index of disease severity, or
as an inflammatory disorder.
Interaction of coagulation and inflammation
It is now recognized that acute sepsis involves a complex
interaction between the coagulation system and the
inflammatory system that may result in organ dysfunction.
The molecule that may be considered central to these
effects is thrombin. In addition to its well-known procoagu-
lation effects, thrombin may have anticoagulation effects
through Protein C activation and induction of prostacyclin
(Fig. 1). Thrombin may also cause cell proliferation and
inflammation through induction of adhesion molecules and
platelet-activating factor activation.
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Abstract
Severe sepsis, defined as sepsis associated with acute organ dysfunction, results from a generalized
inflammatory and procoagulant host response to infection. Coagulopathy in severe sepsis is commonly
associated with multiple organ dysfunction, and often results in death. The molecule that is central to
these effects is thrombin, although it may also have anticoagulant and antithrombotic effects through
the activation of Protein C and induction of prostacyclin. In recent years, it has been recognized that
chemicals produced by endothelial cells play a key role in the pathogenesis of sepsis. Thrombomodulin
on endothelial cells coverts Protein C to Activated Protein C, which has important antithrombotic,
profibrinolytic and anti-inflammatory properties. A number of studies have shown that Protein C levels
are reduced in patients with severe infection, or even in inflammatory states without infection. Because
coagulopathy is associated with high mortality rates, and animal studies have indicated that therapeutic
intervention may result in improved outcomes, it was rational to initiate clinical studies.
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The interaction between coagulation and inflammation
has been demonstrated in a number of animal studies in
which anticoagulant therapies, including heparin [1,2],
antithrombin [3,4], tissue factor (TF) pathway inhibitor
[5–7] and Activated Protein C [8], were shown to influ-
ence the inflammatory response. It is also now clear that
both the coagulation and the fibrinolytic systems may be
altered in acute sepsis, with the balance tipped in favour
of procoagulation (through increased TF and thrombin
expression, with decreased activation of thrombomodulin
and Protein C) and antifibrinolysis (through plasminogen
activator inhibitor [PAI]-1 expression). In experimental
models in which very small doses of endotoxin or tumour
necrosis factor (TNF) are given to volunteers, there is ini-
tially a profibrinolytic response, followed by an antifibri-
nolytic response, which corresponds to a procoagulant
state (Fig. 2).
Considering the coagulation cascade as a whole, it is the
extrinsic pathway (via TF and thrombin activation) rather
than the intrinsic pathway that is of primary importance in
sepsis. Once coagulation has been triggered by TF activa-
tion, leading to thrombin formation, this can have further
procoagulant effects, because thrombin itself can activate
factors VIII, IX and X. This is normally balanced by the pro-
duction of anticoagulant factors, such as TF pathway
inhibitor, antithrombin and Activated Protein C. However,
there are other contributors to the processes of pro-/anti-
coagulation and inflammation, including monocytes,
macrophages, platelets and, importantly, endothelial cells.
Role of endothelial cells
In recent years, it has been recognized that endothelial
cells play a key role in the pathogenesis of sepsis, and that
they produce important regulators of both coagulation and
inflammation. They can express or release a number of
substances, such as TF, endothelin-1 and PAI-1, which
promote the coagulation process, as well as other sub-
stances, such as antithrombin, thrombomodulin, nitric
oxide and prostacyclin, which inhibit it (Fig. 3). Thrombo-
modulin is to anticoagulation what TF is to coagulation.
That is, the binding of thrombin to thrombomodulin on
endothelial cells results in Protein C activation. Once acti-
vated, Protein C binds to its cofactor, Protein S (either
freely circulating or bound to C4b-binding protein), and
Activated Protein C inhibits the coagulation factors Va and
VIIIa. Activated Protein C may also neutralize PAI-1, result-
ing in increased fibrinolysis, which represents an important
difference between Activated Protein C and other anti-
coagulant substances, such as antithrombin. Activated
Protein C also has important anti-inflammatory properties.
It may inhibit E-selectin-mediated cell adhesion, or genera-
tion of interleukin-1 and TNF by monocytes, and may also
uncouple the lipopolysaccharide (endotoxin) interaction
with CD14 receptors.
Decreased Protein C in disease
Protein C is the source of Activated Protein C. Although
Protein C is a biomarker or indicator of sepsis, it has no
known specific biological activity. Protein C is converted
to Activated Protein C in the presence of normal
endothelium. In patients with severe sepsis, the vascular
endothelium becomes damaged, levels of endothelial
Figure 1
Central role of thrombin in acute sepsis. PAF, platelet-activating factor;
PGI2, prostacyclin; PMN, polymorphonuclear leukocyte.
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ANTITHROMBOLYSIS
PROCOAGULATION
Expression of P- and E- sections
PMN activation and chemotaxis
PAF activation
ANTICOAGULATION
Fibrin clot formation
Positive feedback
Protein C activation
PGI
2
CELL PROLIFERATION INFLAMMATION
THROMBIN
Figure 2
Experimental model of sepsis in volunteers: Effect of small doses of
endotoxin (lipopolysaccharide [LPS]) or TNF on the fibrinolysis system.
PAP, plasmin–antiplasmin complex; t-PA, tissue plasminogen activator.
LPS TNF
t-PA
PAP PAI-1
TIME
Fibrinolysis
(Procoagulant state)c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
s
u
p
p
l
e
m
e
n
t
thrombomodulin significantly decrease, and the body’s
ability to convert Protein C to Activated Protein C dimin-
ishes. Only when activated does Protein C have antithrom-
botic, profibrinolytic and anti-inflammatory properties.
A number of studies have now shown that Protein C levels
are reduced in patients with severe infection. In the study
by Powars et al [9], Protein C levels were reduced to
approximately 50% of normal levels in patients with moder-
ate meningococcaemia, and to approximately 30% of
normal levels in critically ill patients (Fig. 4). Similarly, a
study by Hemmer et al [10] in patients with malaria showed
that those with complications had much higher levels of
TNF and greatly reduced Protein C activity (Fig. 5). In
patients who have undergone bone marrow transplantion,
low antithrombin and Protein C levels are also the best pre-
dictors of multiple organ dysfunction [11]. In a subgroup of
70 patients with sepsis included in an ibuprofen trial [12],
90% were shown to have low Protein C levels and most
also had other alterations in coagulation factors (elevated
D-dimers, low fibrinogen level and low platelet count). In
that study, there was a significant correlation between the
increase in Protein C levels from 0 to 44 h, and 30-day
mortality (P < 0.01). Furthermore, mortality was higher in
patients with persistently low Protein C levels than in those
whose Protein C levels recovered spontaneously without
any treatment (45% versus 26%).
Coagulation abnormalities can occur in all types of infec-
tion, including both Gram-positive and Gram-negative bac-
terial infections [13–15], or even in the absence of
infection, such as in inflammatory states secondary to
trauma or neurosurgery [16]. Interestingly, they can also
occur in patients with localized disease, such as those with
respiratory infection [17]. In a study by Günther et al [17],
procoagulant activity in bronchial lavage fluid from patients
with pneumonia or acute respiratory distress syndrome
was found to be increased compared with that from control
individuals, with a correlation between the severity of respi-
ratory failure and level of coagulant activity (Fig. 6).
Rationale for clinical studies
It is well documented that DIC in septic shock is associ-
ated with higher mortality rates than is septic shock
without DIC (77% versus 32%) [18]. Higher Sequential
Organ Failure Assessment scores [19] and PAI-1 levels
Available online http://ccforum.com/content/5/S2/S1
Figure 3
Procoagulant and anticoagulant substances that are expressed/released
by endothelial cells. AT, antithrombin; NO, nitric oxide; 
PGI2, prostacyclin; TFPI, TF pathway inhibitor.
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Figure 4
Protein C levels (% of normal) in patients with meningococcaemia.
Adapted from Powars et al [9].
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Figure 5
TNF-a levels (normal range <15 pg/ml) and Protein C activity (normal
range 60–140%) in malaria. Adapted from Hemmer et al [10].
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Furthermore, coagulation is inter-related with inflammation.
Because animal studies indicated that therapeutic inter-
vention may result in improved outcome, a number of clini-
cal studies were initiated.
Recent clinical studies with antithrombin and
Activated Protein C
Early clinical studies with antithrombin III (ATIII) achieved
promising results. In a study by Fourrier et al [21], patients
who were treated with ATIII had a shorter duration of DIC
with no side effects, and no change in Protein C or Protein
S levels. However, a meta-analysis of three placebo-con-
trolled, randomized clinical trials with ATIII in sepsis [22]
demonstrated a nonsignificant reduction in 30-day all-
cause mortality. A phase II clinical trial has identified the
optimum dosage regimen for recombinant human Activated
Protein C, and this has subsequently been used in a large,
multicenter, placebo-controlled, phase III trial.
Conclusion
Severe sepsis, defined as sepsis associated with acute
organ dysfunction, results from a generalized inflammatory
and procoagulant host response to infection. The ultimate
cause of acute organ dysfunction in sepsis is injury to the
vascular endothelium, which can result in microvascular
coagulopathy.
The extrinsic pathway (via TF and thrombin activation) is of
primary importance in sepsis. Thrombomodulin on endothe-
lial cells converts Protein C to Activated Protein C, which
has multiple mechanisms of action that support its anti-
inflammatory, antithrombotic and profibrinolytic properties.
In patients with severe sepsis, the vascular endothelium
becomes damaged, levels of endothelial thrombomodulin
significantly decrease, and the body’s ability to convert
Protein C to Activated Protein C diminishes.
The complex interactions between coagulation and inflam-
mation support the development and use of strategies that
are aimed at improving endothelial cell function, and thus
providing therapeutic intervention to modulate inflamma-
tion and coagulopathy in patients with sepsis and organ
dysfunction. Early clinical studies using recombinant
human Activated Protein C appear promising.
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